A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia
Completed · Phase 2 · NCT04278924
Conditions: Primary Immune Thrombocytopenia
At a glance
- Research payments reported, 2025
- $4,800
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 41
About the trial
- Sponsor
- Takeda
- Tested
- Placebo (drug), TAK-079 (drug)
- Dates
- Started 2020-11-09; completion 2024-04-29
- Results posted
- Yes
Primary immune thrombocytopenia (ITP) is a rare disease that results in low levels of platelets - the cells that help blood clot. The main aim of the study is to check for side effects from taking TAK-079 at three different dose levels. Another aim is to learn if TAK-079 can increase the platelet count in people with ITP. In addition to receiving stable background therapy for ITP, participants will receive an injection of either TAK-079 or a placebo once a week for 2 months. A placebo looks like TAK-079 but will not have any medicine in it. After treatment, all participants will be followed-up for another 2 months. Then, participants who received TAK-079 will continue to be followed-up fo…
From ClinicalTrials.gov, last updated 2025-06-15. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Takeda Pharmaceuticals U.S.A., Inc. reported $4,800 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $4,800
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.